Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence
Summary
The objective of this study is to evaluate the efficacy of mecamylamine (MEC, 10 mg/day) versus placebo in reducing depressive and alcohol symptoms in patients with depression and co-morbid alcohol dependence. The researchers hypothesize that MEC will significantly reduce depressive symptoms and decrease alcohol consumption compared to placebo in patients with depression and alcohol dependence who are on a stable dose of a selective serotonin reuptake inhibitor (SSRI).
Timeline
- Start
- 2007-08
- Primary completion
- 2014-07
- Completion
- 2014-07
Outcome
Mixed primary results
registry MEAN Placebo: 17.6 (Standard Deviation 6.570) days NCT00563797 ↗
registry MEAN Mecamylamine: 12.6 (Standard Deviation 6.570) days NCT00563797 ↗
registry analysis (superiority or other test); Placebo; p = 0.014; Mixed Models Analysis; note: F=7.73 NCT00563797 ↗
registry MEAN Mecamylamine: 8.212 (Standard Deviation 1.592) units on a scale NCT00563797 ↗
registry MEAN Placebo: 8.10 (Standard Deviation 1.60) units on a scale NCT00563797 ↗
registry analysis (superiority or other test); Mecamylamine; p = .0001; Mixed Models Analysis; note: F=36.32 NCT00563797 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mecamylamine | Small molecule | 10 mg | — |